By the way, details of the Poster session are already on the ATS website:
Poster Discussion Session: Tuesday, May 20, 8:15 AM - 10:45AM,
Sapphire Ballroom E-F (Level 4), Hilton San Diego Bayfront
Poster Viewing: 8:15-9:15, Discussion: 9:15-10:45
A Randomized, Double-Blind, Placebo-Controlled Study Of Liposomal Amikacin For Inhalation (Arikace®) In Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
C27 | DIAGNOSIS AND TREATMENT OF NONTUBERCULOUS MYCOBACTERIA INFECTIONS
The abstract has a few more interesting details:
90 randomized 19% CF, 81% non CF
64% MAC, 36% M-Abs
90 started, 1 died
72 continued into open label
41 of which have already finished
the deadline for poster submission is March 30th (because they are peer reviewed); therefore insmed knows a lot more detail than was discussed yesterday.
insmed is an exhibitor too (booth #2933)
By the way, the abstract refers to 590mg dosage (as did yesterday's PR). Curious: it has always been 560mg until now. typo? hmmm...
Also (keep in mind) by mid-May the FDA MUST respond (with 60 calendar days) to Insmed's request regarding Breakthrough Therapy
The poster will contain more details/data from the trial.
At least one knowledgeable expert will be on hand stood next to the poster to answer questions (for about 90 mins - the poster stays up all day).
In addition, Felix Ratjen is chairing a separate technical session (I think on Weds) which is also related.
It's all on the ATS site.
I would like to go, but probably can't (other commitments).
I expect FDA to say "yes" to Breakthrough Therapy by then anyway and I expect Insmed to publish the poster on their website (perhaps the day after).